Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study

2014 ◽  
Vol 12 (4) ◽  
pp. 452-458 ◽  
Author(s):  
W.-S. Chung ◽  
C.-L. Lin ◽  
S.-N. Chang ◽  
C.-C. Lu ◽  
C.-H. Kao
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pulmonary Embolism ◽  
Cohort Study ◽  
Deep Vein Thrombosis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals From TTP to Glomerulonephritis: A Lifetime of Lupus

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Fadi Kharouf ◽  
Sigal Shahar ◽  
Yoav Hershkovitz ◽  
Alaa Shaheen ◽  
Areej Bayatra ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Disease Course ◽  
Systemic Lupus ◽  
Thrombocytopenic Purpura ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Excellent Clinical Outcome

We report the case of a 56-year-old male patient, who over two decades, sequentially presented with a combination of clinical manifestations. These included thrombotic thrombocytopenic purpura (TTP), right leg deep vein thrombosis (DVT), and eventually constitutional symptoms, arthralgia, diffuse lymphadenopathy, pancytopenia, skin rash, pericarditis, and glomerulonephritis. Serologic tests and renal pathology uncovered a diagnosis of systemic lupus erythematosus (SLE), and immunosuppressive therapy was initiated. Soon after, the patient developed striking cytomegalovirus (CMV) viremia, requiring prolonged antiviral therapy and reduction of immunosuppression. Finally, an acute embolic stroke complicated the disease course. Prompt interventions allowed an excellent clinical outcome.

Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupus erythematosus

2000 ◽  
Vol 159 (3) ◽  
pp. 211-214 ◽  
Author(s):  
Marco Gattorno ◽  
Angelo Claudio Molinari ◽  
Antonella Buoncompagni ◽  
Maura Acquila ◽  
Stefano Amato ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis

Lupus ◽  
2020 ◽  
Vol 29 (5) ◽  
pp. 490-498
Author(s):  
O Tkachenko ◽  
S Lapin ◽  
A Mazing ◽  
V Emanuel ◽  
E Belolipetskaia ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Confidence Interval ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Odds Ratio ◽  
Arterial Thrombosis ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

To reveal the clinical significance of criteria and non-criteria antiphospholipid antibodies detected by line immunoassay in comparison with ELISA, systemic lupus erythematosus patients with and without thrombotic events were investigated. Thus, 107 systemic lupus erythematosus patients (48% with deep vein thrombosis or/and arterial thrombosis) and 120 healthy donors were enrolled. Serum antiphospholipid antibodies were detected by ELISA (Orgentec Diagnostika, Germany) and line immunoassay (GA Generic Assays, Germany). Lupus anticoagulant and IgG to cardiolipin and β2GPI but not IgM as well as triple positivity by ELISA and line immunoassay were linked with thrombosis in systemic lupus erythematosus. IgG to phosphatidylinositol and phosphatidylserine by line immunoassay showed significantly higher levels in systemic lupus erythematosus with deep vein thrombosis/arterial thrombosis than without and were independent risk factors for deep vein thrombosis (odds ratio 3.9, 95% confidence interval 1.1, 13.2) and arterial thrombosis (odds ratio 5.1, 95% confidence interval 1.3, 19.8) as well as thrombosis (odds ratio 3.6, 95% confidence interval 1.1, 11.3) and recurrence thereof (odds ratio 6.9, 95% confidence interval 2.1, 22.6), respectively. The occurrence of >4 IgG antiphospholipid antibodies by line immunoassay was an independent risk factor for thrombosis (odds ratio 10.9, 95% confidence interval 1.2, 101.5), arterial thrombosis (odds ratio 14.6, 95% confidence interval 2.5, 86.3), deep vein thrombosis (odds ratio 5.8, 95% confidence interval 1.0, 32.4) and recurrence of thrombosis (odds ratio 35.9, 95% confidence interval 3.8, 342.8). Line immunoassay is a promising multiplex test for the simultaneous detection of criteria and non-criteria antiphospholipid antibodies. Profiling of antiphospholipid antibodies by line immunoassay can differentiate systemic lupus erythematosus patients with thrombosis from systemic lupus erythematosus patients without and assess the risk for thrombosis and recurrence thereof.

scholarly journals Primary Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) with Multiple Deep Vein Thrombosis- Case Report

2020 ◽  
Vol 8 (10) ◽  
pp. 882-885
Author(s):  
Dr. Krishna Kumar Dhakchinamoorthi ◽  
Dr. Ann Mary Alex ◽  
Dr. Nikhil Cherian Sam ◽  
Dr. Jeevanantham R ◽  
Mohamed Sulaiman G ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Case Report ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Primary Antiphospholipid Syndrome ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
Deep Vein

A significant improvement of thromboses treated by a new oral anticoagulant in an 11-year-old girl with systemic lupus erythematosus associated antiphospholipid syndrome: A case report

Lupus ◽  
2021 ◽  
pp. 096120332110160
Author(s):  
Yen-Jung Chiang ◽  
Ya-Chiao Hu ◽  
Bor-Luen Chiang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Deep Vein Thrombosis ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Oral Anticoagulants ◽  
Close Monitoring ◽  
Systemic Lupus ◽  
Vein Thrombosis ◽  
New Oral Anticoagulant ◽  
Deep Vein

Pediatric venous thrombosis is associated with a variety of chronic diseases. Antiphospholipid syndrome (APS) is one of them and is commonly related to systemic lupus erythematosus (SLE). Warfarin is the mainstream of anticoagulation treatment in pediatric APS currently but it needs close monitoring and frequent dose adjustment. New oral anticoagulants (NOAC) is one of the innovative options in recent years but there is a lack of report in secondary prevention of deep vein thrombosis (DVT), especially pediatric APS. Herein we reported the significant therapeutic effect of edoxaban in a 11-year-old girl of newly diagnosed SLE and APS, who had deep vein thrombosis as the initial presentation.

scholarly journals Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e038102
Author(s):  
Alison Evans ◽  
Miranda Davies ◽  
Vicki Osborne ◽  
Debabrata Roy ◽  
Saad Shakir
Keyword(s):  
Pulmonary Embolism ◽  
Cohort Study ◽  
Deep Vein Thrombosis ◽  
Major Bleeding ◽  
Secondary Care ◽  
Observational Cohort Study ◽  
Vein Thrombosis ◽  
Prevention And Treatment ◽  
Observational Cohort ◽  
Deep Vein

ObjectivesTo evaluate the short-term (12 weeks) safety and utilisation of rivaroxaban prescribed to new-user adult patients for the treatment of deep vein thrombosis and pulmonary embolism and for the prevention of recurrent deep vein thrombosis and pulmonary embolism in a secondary care setting in England and Wales.DesignAn observational cohort study using the technique of Specialist Cohort Event Monitoring.SettingThe Rivaroxaban Observational Safety Evaluation study was conducted across 87 participating National Health Service secondary care trusts in England and Wales.Participants1532 patients treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism from September 2013 to January 2016.InterventionsNon-interventional postauthorisation safety study of rivaroxaban.Primary and secondary outcome measures(1) Risk of major bleeding in gastrointestinal, intracranial, and urogenital sites and (2) risk of all major and clinically relevant non-major bleeds.ResultsOf a total of 4846 patients enrolled in the study from September 2013 to January 2016, 1532 were treated with rivaroxaban for the prevention and treatment of deep vein thrombosis/pulmonary embolism. The median age of the deep vein thrombosis/pulmonary embolism cohort was 63 years, and 54.6% were men. The risk of major bleeding within the gastrointestinal, urogenital and intracranial primary sites was 0.7% (n=11), 0.3% (n=5) and 0.1% (n=1), respectively. The risk of major bleeding in all sites was 1.5% (n=23) at a rate of 8.3 events per 100 patient-years.ConclusionsIn terms of the primary outcome risk of major bleeding in gastrointestinal, intracranial and urogenital sites, the risk estimates in the population using rivaroxaban for deep vein thrombosis/pulmonary embolism were low (<1%) and consistent with the risk estimated from clinical trial data and in routine clinical practice.Trial registration numbersClinicalTrials.gov Registry (NCT01871194); ENCePP Registry (EUPAS3979).

Sign in / Sign up

Export Citation Format

Share Document